Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

The complex entanglement of Hippo-Yap/Taz signaling in tumor immunity

Oncogene volume 38, pages 2899–2909 (2019)Cite this article

Subjects

Abstract

The Hippo-Yap/Taz pathway, originally identified as a central developmental regulator of organ size, has been found perturbed in many types of human tumors, and linked to tumor growth, survival, evasion, metastasis, stemness, and drug resistance. Beside these tumor-cell-intrinsic functions, Hippo signaling also plays important immune-regulatory roles. In this review, we will summarize and discuss recent breakthroughs in our understanding of how various components of the Hippo-Yap/Taz pathway influence the tumor immune microenvironment, including their effects on the tumor secretome and immune infiltrates, their roles in regulating crosstalk between tumor cells and T cells, and finally their intrinsic functions in various types of innate and adaptive immune cells. While further research is needed to integrate and reconcile existing findings and to discern the overall effects of Hippo signaling on tumor immunity, it is clear that Hippo signaling functions as a key bridge connecting tumor cells with both the adaptive and innate immune systems. Thus, all future therapeutic development against the Hippo-Yap/Taz pathway should take into account their multi-faceted roles in regulating tumor immunity in addition to their growth-regulatory functions. Given that immune therapies have become the mainstay of cancer treatment, it is also important to pursue how to manipulate Hippo signaling to boost response or overcome resistance to existing immune therapies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Zappasodi R, Merghoub T, Wolchok JD. Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell. 2018;33:581–98.

    Article  CAS  Google Scholar 

  2. Moynihan KD, Irvine DJ. Roles for innate immunity in combination immunotherapies. Cancer Res. 2017;77:5215–21.

    Article  CAS  Google Scholar 

  3. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21:2747–61.

    Article  CAS  Google Scholar 

  4. Lei Q-Y, Zhang H, Zhao B, Zha Z-Y, Bai F, Pei X-H, et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol. 2008;28:2426–36.

    Article  CAS  Google Scholar 

  5. Liu C-Y, Zha Z-Y, Zhou X, Zhang H, Huang W, Zhao D, et al. The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF β-TrCP E3 Ligase. J Biol Chem. 2010;285:37159–69.

    Article  CAS  Google Scholar 

  6. Zhao B, Li L, Tumaneng K, Wang C-Y, Guan K-L. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCFβ-TRCP. Genes Dev. 2010;24:72–85.

    Article  CAS  Google Scholar 

  7. Moon S, Yeon Park S, Woo Park H. Regulation of the Hippo pathway in cancer biology. Cell Mol Life Sci. 2018;75:2303–19.

    Article  CAS  Google Scholar 

  8. Fu V, Plouffe SW, Guan K-L. The Hippo pathway in organ development, homeostasis, and regeneration. Curr Opin Cell Biol. 2017;49:99–107.

    Article  CAS  Google Scholar 

  9. Galan JA, Avruch J. MST1/MST2 Protein Kinases: Regulation and Physiologic Roles. Biochemistry. 2016;55:5507–19.

    Article  CAS  Google Scholar 

  10. Furth N, Aylon Y. The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway. Cell Death Differ. 2017;24:1488–501.

    Article  CAS  Google Scholar 

  11. Padmanee Sharma, Siwen Hu-Lieskovan, Jennifer A Wargo and Antoni Ribas. Primary, Adaptive, and Acquired Resistance to CancerImmunotherapy. Cell Rev. 2017; 168. http://ac.els-cdn.com/S009286741730065X/1-s2.0-S009286741730065X-main.pdf?_tid=8c86f758-4a19-11e7-b4b0-00000aab0f6c&acdnat=1496686105_798335971803e859ab3b6cce754a7276.

  12. Kim MH, Kim CG, Kim S-K, Shin SJ, Choe EA, Park S-H et al. YAP-induced PD-L1 expression drives immune evasion in BRAFi-resistant melanoma. Cancer Immunol Res. 2018; canimm.0320.2017.

  13. Lee BS, Park DIl, Lee DH, Lee JE, Yeo M, Park YH, et al. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma. Biochem Biophys Res Commun. 2017;491:493–9.

    Article  CAS  Google Scholar 

  14. Janse van Rensburg HJ, Azad T, Ling M, Hao Y, Snetsinger B, Khanal P, et al. The hippo pathway component TAZ promotes immune evasion in human cancer through PD-L1. Cancer Res. 2018;78:1457–70.

    Article  CAS  Google Scholar 

  15. Miao J, Hsu P-C, Yang Y-L, Xu Z, Dai Y, Wang Y, et al. YAP regulates PD-L1 expression in human NSCLC cells. Oncotarget. 2017;8:114576–87.

    PubMed  PubMed Central  Google Scholar 

  16. Schupp J, Krebs FK, Zimmer N, Trzeciak E, Schuppan D, Tuettenberg A Targeting myeloid cells in the tumor sustaining microenvironment. Cell. Immunol. 2017. https://doi.org/10.1016/j.cellimm.2017.10.013.

  17. Sica A, Massarotti M. Myeloid suppressor cells in cancer and autoimmunity. J Autoimmun. 2017;85:117–25.

    Article  CAS  Google Scholar 

  18. Wang G, Lu X, Dey P, Deng P, Wu CC, Jiang S, et al. Targeting YAP-dependent MDSC infiltration impairs tumor progression. Cancer Discov. 2016;6:80–95.

    Article  Google Scholar 

  19. Murakami S, Shahbazian D, Surana R, Zhang W, Chen H, Graham GT, et al. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. Oncogene. 2017;36:1232–44.

    Article  CAS  Google Scholar 

  20. Kim T, Yang SJ, Hwang D, Song J, Kim M, Kyum Kim S et al. A basal-like breast cancer-specific role for SRF-IL6 in YAP-induced cancer stemness. Nat Commun 2015; 6. https://doi.org/10.1038/ncomms10186.

  21. Guo X, Zhao Y, Yan H, Yang Y, Shen S, Dai X, et al. Single tumor-initiating cells evade immune clearance by recruiting type II macrophages. Genes Dev. 2017;31:247–59.

    Article  CAS  Google Scholar 

  22. Kim W, Khan SK, Liu Y, Xu R, Park O, He Y et al. Hepatic Hippo signaling inhibits protumoural microenvironment to suppress hepatocellular carcinoma. Gut. 2017. https://doi.org/10.1136/gutjnl-2017-314061.

    Article  Google Scholar 

  23. Gascard P, Tlsty TD. Carcinoma-associated fibroblasts: Orchestrating the composition of malignancy. Genes Dev. 2016;30:1002–19.

    Article  CAS  Google Scholar 

  24. von Ahrens D, Bhagat TD, Nagrath D, Maitra A, Verma A. The role of stromal cancer-associated fibroblasts in pancreatic cancer. J Hematol Oncol. 2017;10:76.

    Article  Google Scholar 

  25. Zhang W, Nandakumar N, Shi Y, Manzano M, Smith A, Graham G, et al. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci Signal. 2014;7:ra42.

    Article  Google Scholar 

  26. Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol. 2013;15:637–46.

    Article  CAS  Google Scholar 

  27. Laklai H, Miroshnikova YA, Pickup MW, Collisson EA, Kim GE, Barrett AS, et al. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat Med. 2016;22:497–505.

    Article  CAS  Google Scholar 

  28. Foster CT, Gualdrini F, Treisman R. Mutual dependence of the MRTF–SRF and YAP–TEAD pathways in cancer-associated fibroblasts is indirect and mediated by cytoskeletal dynamics. Genes Dev. 2017;31:2361–75.

    Article  CAS  Google Scholar 

  29. Liu F, Lagares D, Choi KM, Stopfer L, Marinković A, Vrbanac V, et al. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. Am J Physiol Cell Mol Physiol. 2015;308:L344–L357.

    Article  CAS  Google Scholar 

  30. Nardone G, Oliver-De La Cruz J, Vrbsky J, Martini C, Pribyl J, Skládal P et al. YAP regulates cell mechanics by controlling focal adhesion assembly. Nat Commun 2017; 8. https://doi.org/10.1038/ncomms15321.

    Article  CAS  Google Scholar 

  31. Aragona M, Panciera T, Manfrin A, Giulitti S, Michielin F, Elvassore N, et al. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell. 2013;154:1047–59.

    Article  CAS  Google Scholar 

  32. Furukawa KT, Yamashita K, Sakurai N, Ohno S. The epithelial circumferential actin belt regulates YAP/TAZ through nucleocytoplasmic shuttling of merlin. Cell Rep. 2017;20:1435–47.

    Article  CAS  Google Scholar 

  33. Sansores-Garcia L, Bossuyt W, Wada KI, Yonemura S, Tao C, Sasaki H, et al. Modulating F-actin organization induces organ growth by affecting the Hippo pathway. EMBO J. 2011;30:2325–35.

    Article  CAS  Google Scholar 

  34. Elosegui-Artola A, Oria R, Chen Y, Kosmalska A, Pérez-González C, Castro N, et al. Mechanical regulation of a molecular clutch defines force transmission and transduction in response to matrix rigidity. Nat Cell Biol. 2016;18:540–8.

    Article  CAS  Google Scholar 

  35. Meng Z, Qiu Y, Lin KC, Kumar A, Placone JK, Fang C, et al. RAP2 mediates mechanoresponses of the Hippo pathway. Nature. 2018;560:655–60.

    Article  CAS  Google Scholar 

  36. Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med. 2016;22:851–60.

    Article  CAS  Google Scholar 

  37. Ehmer U, Zmoos AF, Auerbach RK, Vaka D, Butte AJ, Kay MA, et al. Organ size control is dominant over Rb family inactivation to restrict proliferation invivo. Cell Rep. 2014;8:371–81.

    Article  CAS  Google Scholar 

  38. Miyamura N, Hata S, Itoh T, Tanaka M, Nishio M, Itoh M et al. YAP determines the cell fate of injured mouse hepatocytes in vivo. Nat Commun 2017;8. https://doi.org/10.1038/ncomms16017.

    Article  CAS  Google Scholar 

  39. Moroishi T, Hayashi T, Pan W-W, Fujita Y, Holt MV, Qin J, et al. The hippo pathway kinases LATS1/2 Suppress cancer immunity. Cell. 2016;167:1525–.e17.

    Article  CAS  Google Scholar 

  40. Lee D-H, Park JO, Kim T-S, Kim S-K, Kim T-H, Kim M-C, et al. LATS-YAP/TAZ controls lineage specification by regulating TGFβ signaling and Hnf4α expression during liver development. Nat Commun. 2016;7:11961.

    Article  CAS  Google Scholar 

  41. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol. 2007;9:493–505.

    Article  CAS  Google Scholar 

  42. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. 2011;479:547–51.

    Article  CAS  Google Scholar 

  43. Acosta JC, Banito A, Wuestefeld T, Georgilis A, Janich P, Morton JP, et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol. 2013;15:978–90.

    Article  CAS  Google Scholar 

  44. Cisowski J, Sayin VI, Liu M, Karlsson C, Bergo MO. Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF. Oncogene. 2016;35:1328–33.

    Article  CAS  Google Scholar 

  45. Abdollahpour H, Appaswamy G, Kotlarz D, Diestelhorst J, Beier R, Schäffer AA, et al. The phenotype of human STK4 deficiency. Blood. 2012;119:3450–7.

    Article  CAS  Google Scholar 

  46. Nehme NT, Schmid JP, Debeurme F, André-Schmutz I, Lim A, Nitschke P, et al. MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T-cell survival. Blood. 2012;119:3458–68.

    Article  CAS  Google Scholar 

  47. Bai X, Huang L, Niu L, Zhang Y, Wang J, Sun X, et al. Mst1 positively regulates B-cell receptor signaling via CD19 transcriptional levels. Blood Adv. 2016;1:219–30.

    Article  CAS  Google Scholar 

  48. Zhou D, Medoff BD, Chen L, Li L, Zhang X, Praskova M, et al. The Nore1B/Mst1 complex restrains antigen receptor-induced proliferation of naïve T cells. Proc Natl Acad Sci USA. 2008;105:20321–6.

    Article  CAS  Google Scholar 

  49. Choi J, Oh S, Lee D, Oh HJ, Park JY, Lee SB, et al. Mst1-FoxO signaling protects Naive T lymphocytes from cellular oxidative stress in mice. PLoS ONE. 2009;4:e8011.

    Article  Google Scholar 

  50. Du X, Shi H, Li J, Dong Y, Liang J, Ye J, et al. Mst1/Mst2 regulate development and function of regulatory T cells through modulation of Foxo1/Foxo3 stability in autoimmune disease. J Immunol. 2014;192:1525–35.

    Article  CAS  Google Scholar 

  51. Ueda Y, Katagiri K, Tomiyama T, Yasuda K, Habiro K, Katakai T et al. Mst1 regulates integrin-dependent thymocyte trafficking and antigen recognition in the thymus. Nat Commun. 2012; 3. https://doi.org/10.1038/ncomms2105.

  52. Dong Y, Du X, Ye J, Han M, Xu T, Zhuang Y, et al. A cell-intrinsic role for Mst1 in regulating thymocyte egress. J Immunol. 2009;183:3865–72.

    Article  CAS  Google Scholar 

  53. Mou F, Praskova M, Xia F, Van Buren D, Hock H, Avruch J, et al. The Mst1 and Mst2 kinases control activation of rho family GTPases and thymic egress of mature thymocytes. J Exp Med. 2012;209:741–59.

    Article  CAS  Google Scholar 

  54. Katagiri K, Imamura M, Kinashi T. Spatiotemporal regulation of the kinase Mst1 by binding protein RAPL is critical for lymphocyte polarity and adhesion. Nat Immunol. 2006;7:919–28.

    Article  CAS  Google Scholar 

  55. Katagiri K, Katakai T, Ebisuno Y, Ueda Y, Okada T, Kinashi T. Mst1 controls lymphocyte trafficking and interstitial motility within lymph nodes. EMBO J. 2009;28:1319–31.

    Article  CAS  Google Scholar 

  56. Xu X, Jaeger ER, Wang X, Lagler-Ferrez E, Batalov S, Mathis NL et al. Mst1 directs myosin IIa partitioning of low and higher affinity integrins during T cell migration. PLoS ONE 2014; 9. https://doi.org/10.1371/journal.pone.0105561.

    Article  Google Scholar 

  57. Nishikimi A, Ishihara S, Ozawa M, Etoh K, Fukuda M, Kinashi T et al. Rab13 acts downstream of the kinase Mst1 to deliver the integrin LFA-1 to the cell surface for lymphocyte trafficking. Sci Signal. 2014; 7. https://doi.org/10.1126/scisignal.2005199.

    Article  Google Scholar 

  58. Knochelmann HM, Dwyer CJ, Bailey SR, Amaya SM, Elston DM, Mazza-McCrann JM, et al. When worlds collide: Th17 and Treg cells in cancer and autoimmunity. Cell Mol Immunol. 2018;15:458–69.

    Article  CAS  Google Scholar 

  59. Li J, Du X, Shi H, Deng K, Chi H, Tao W. Mammalian sterile 20-like kinase 1 (Mst1) enhances the stability of forkhead box P3 (Foxp3) and the function of regulatory T cells by modulating Foxp3 acetylation. J Biol Chem. 2015;290:30762–70.

    Article  CAS  Google Scholar 

  60. Geng J, Yu S, Zhao H, Sun X, Li X, Wang P, et al. The transcriptional coactivator TAZ regulates reciprocal differentiation of TH17 cells and Treg cells. Nat Immunol. 2017;18:800–12.

    Article  CAS  Google Scholar 

  61. Li C, Bi Y, Li Y, Yang H, Yu Q, Wang J, et al. Dendritic cell MST1 inhibits Th17 differentiation. Nat Commun. 2017;8:14275.

    Article  CAS  Google Scholar 

  62. Ni X, Tao J, Barbi J, Chen Q, Park BV, Li Z et al. YAP is essential for Treg mediated suppression of anti-tumor immunity. Cancer Discov. 2018; CD-17-1124.

  63. Lo B, Abdel-Motal UM. Lessons from CTLA-4 deficiency and checkpoint inhibition. Curr Opin Immunol. 2017;49:14–9.

    Article  CAS  Google Scholar 

  64. Thaventhiran JED, Hoffmann A, Magiera L, de la Roche M, Lingel H, Brunner-Weinzierl M, et al. Activation of the Hippo pathway by CTLA-4 regulates the expression of Blimp-1 in the CD8+T cell. Proc Natl Acad Sci. 2012;109:E2223–9.

    Article  CAS  Google Scholar 

  65. Murphy TL, Grajales-Reyes GE, Wu X, Tussiwand R, Briseño CG, Iwata A, et al. Transcriptional control of dendritic cell development. Annu Rev Immunol. 2016;34:93–119.

    Article  CAS  Google Scholar 

  66. Du X, Wen J, Wang Y, Karmaus PWF, Khatamian A, Tan H, et al. Hippo/Mst signalling couples metabolic state and immune function of CD8α+dendritic cells. Nature. 2018;558:141–5.

    Article  CAS  Google Scholar 

  67. Cen X, Liu S, Cheng K. The role of Toll-like receptor in inflammation and tumor immunity. Front Pharmacol. 2018;9:878.

    Article  Google Scholar 

  68. Liu B, Zheng Y, Yin F, Yu J, Silverman N, Pan D. Toll receptor-mediated hippo signaling controls innate immunity in drosophila. Cell. 2016;164:406–19.

    Article  CAS  Google Scholar 

  69. Geng J, Sun X, Wang P, Zhang S, Wang X, Wu H, et al. Kinases Mst1 and Mst2 positively regulate phagocytic induction of reactive oxygen species and bactericidal activity. Nat Immunol. 2015;16:1142–52.

    Article  CAS  Google Scholar 

  70. Boro M, Singh V, Balaji KN. Mycobacterium tuberculosis-triggered Hippo pathway orchestrates CXCL1/2 expression to modulate host immune responses. Sci Rep 2016; 6. https://doi.org/10.1038/srep37695.

  71. Yuan L, Mao Y, Luo W, Wu W, Xu H, Wang XL et al. Palmitic acid dysregulates the Hippo–YAP pathway and inhibits angiogenesis by inducing mitochondrial damage and activating the cytosolic DNA sensor cGAS–STING–IRF3 signaling mechanism. 2017. https://doi.org/10.1074/jbc.M117.804005.

    Article  CAS  Google Scholar 

  72. Li W, Xiao J, Zhou X, Xu M, Hu C, Xu X, et al. STK4 regulates TLR pathways and protects against chronic inflammation-related hepatocellular carcinoma. J Clin Invest. 2015;125:4239–54.

    Article  Google Scholar 

  73. Dubey SK, Tapadia MG.Yorkie regulates neurodegeneration through canonical pathway and innate immune response. Mol. Neurobiol. 2018;55:1193–207.

    Article  CAS  Google Scholar 

  74. Luecke S, Paludan SR. Molecular requirements for sensing of intracellular microbial nucleic acids by the innate immune system. Cytokine. 2017;98:4–14.

    Article  CAS  Google Scholar 

  75. Iurescia S, Fioretti D, Rinaldi M. Targeting cytosolic nucleic acid-sensing pathways for cancer immunotherapies. Front Immunol. 2018;9:711.

    Article  Google Scholar 

  76. Meng F, Zhou R, Wu S, Zhang Q, Jin Q, Zhou Y, et al. Mst1 shuts off cytosolic antiviral defense through IRF3 phosphorylation. Genes Dev. 2016;30:1086–100.

    Article  CAS  Google Scholar 

  77. Wang S, Xie F, Chu F, Zhang Z, Yang B, Dai T, et al. YAP antagonizes innate antiviral immunity and is targeted for lysosomal degradation through IKK[epsiv]-mediated phosphorylation. Nat Immunol. 2017;18:733–43.

    Article  CAS  Google Scholar 

  78. Zhang Q, Meng F, Chen S, Plouffe SW, Wu S, Liu S, et al. Hippo signalling governs cytosolic nucleic acid sensing through YAP/TAZ-mediated TBK1 blockade. Nat Cell Biol. 2017;19:362–74.

    Article  CAS  Google Scholar 

  79. Jiao S, Guan J, Chen M, Wang W, Li C, Wang Y, et al. Targeting IRF3 as a YAP agonist therapy against gastric cancer. J Exp Med. 2018;215:699–718.

    Article  CAS  Google Scholar 

  80. Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170:1109–.e10.

    Article  CAS  Google Scholar 

  81. Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, et al. Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Sci Transl Med. 2018;10:eaam7577.

    Article  Google Scholar 

  82. Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 2014;6:226ra32–226ra32.

    Article  Google Scholar 

  83. Liu Z, Ravindranathan R, Kalinski P, Guo ZS, Bartlett DL. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun. 2017;8:14754.

    Article  CAS  Google Scholar 

  84. Ramjee V, Li D, Manderfield LJ, Liu F, Engleka KA, Aghajanian H, et al. Epicardial YAP/TAZ orchestrate an immunosuppressive response following myocardial infarction. J Clin Invest. 2017;127:899–911.

    Article  Google Scholar 

  85. Jiao S, Guan J, Chen M, Wang W, Li C, Wang Y et al. Targeting IRF3 as a YAP agonist therapy against gastric cancer. J Exp Med. 2018. https://doi.org/10.1084/jem.20171116.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Research in Yi lab is currently supported by NIH (R01CA187090), Toulmin Pilot Award, Sher Grant and Cancer Center Support Grant (CA051008). Shannon White is a current recipient of National Science Foundation Graduate Research Fellowship (NSF-GRF#2018265935).

Author information

Author notes

  1. These authors contributed equally: Shannon M. White, Shigekazu Murakami

Authors and Affiliations

  1. Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA

    Shannon M. White, Shigekazu Murakami & Chunling Yi

Authors
  1. Shannon M. White
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shigekazu Murakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chunling Yi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chunling Yi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

White, S.M., Murakami, S. & Yi, C. The complex entanglement of Hippo-Yap/Taz signaling in tumor immunity. Oncogene 38, 2899–2909 (2019). https://doi.org/10.1038/s41388-018-0649-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41388-018-0649-6

This article is cited by

Search

Advanced search

Quick links